NIDDK Provides Additional Data From CyNCh Study Evaluating RP103 in Pediatric NASH at AASLD NOVATO, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced researchers have provided additional results from the CyNCh study of RP103 for the treatment...

Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...

Raptor Pharmaceutical to Hold Second Quarter 2015 Financial Results Conference Call and Webcast on Thursday, August 6, 2015, at 4:30 p.m. EDT NOVATO, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2015 financial results on Thursday, August 6,...

Foundation for Mitochondrial Medicine Awards Grant to Functional MRI Study of Children With Mitochondrial Disease ATLANTA, May 15, 2012 (GLOBE NEWSWIRE) -- The Foundation for Mitochondrial Medicine, a US-based non-profit dedicated to funding research for the treatment of mitochondrial disease, has awarded a...